VentureBeat May 3, 2022
George Lawton

LifeOmic, a precision health platform, and XCures, which helps identify cancer treatment options, have partnered to streamline and improve recommendations for cancer care. The companies say the partnership aims to improve accuracy and efficiency in reviewing and analyzing medical documents, which is crucial in preparing data for AI analysis and building medical digital twins to explore the ramifications of various treatment options.

The partnership is designed to combine XCures’ tools in cancer research with LifeOmic’s Precision Health Cloud to make sense of data from health records, medical devices, consumer health watches and new genomics technology. It supports apps for individuals, employers, healthcare organizations and pharmaceutical companies. It has also developed OCR tools that can automate the process of digitizing...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: AI (Artificial Intelligence), Biotechnology, Partnerships, Pharma / Biotech, Technology, Trends
Will Synthetic, AI-Based Digital Humans Change Pharma and Life Sciences? Q&A with Abid Rahman, SVP Innovation, EVERSANA
Cerevel Parkinson’s data adds lustre to AbbVie acquisition
Roche Drug Scores Label Expansion for Earlier Use in Lung Cancer
Pharma Pulse 4/19/24: The Health and Healthcare of Gen-Z, Long-Acting Drugs May Revolutionize HIV Prevention/Treatment & more
Recursion, Canaan, Metsera and more—Chutes & Ladders

Share This Article